Leap Therapeutics, Inc.

Equities

LPTX

US52187K2006

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-16 EDT			5-day change	1st Jan Change
2.24 ^USD	+2.75%		+11.44%	-45.96%

07-01	Leap Therapeutics, Inc.(NasdaqCM:LPTX) added to Russell 3000E Index	CI
07-01	Leap Therapeutics, Inc.(NasdaqCM:LPTX) added to Russell Microcap Index	CI

Leap Therapeutics, Inc. Appoints Atricia Martin and Christian Richard to Board of Directors

January 17, 2023 at 08:01 am

Leap Therapeutics, Inc. announced effective as of the closing of the transactions, Leap has added two members nominated by Flame to its existing eight person Board of Directors: Patricia Martin and Christian Richard.

Latest news about Leap Therapeutics, Inc.

Leap Therapeutics, Inc.(NasdaqCM:LPTX) added to Russell 3000E Index	06-30	CI
Leap Therapeutics, Inc.(NasdaqCM:LPTX) added to Russell Microcap Index	06-30	CI
Leap Therapeutics, Inc.(NasdaqCM:LPTX) added to Russell Microcap Growth Index	06-30	CI
Leap Therapeutics, Inc.(NasdaqCM:LPTX) added to Russell 3000E Growth Index	06-30	CI
Leap Therapeutics, Inc.(NasdaqCM:LPTX) added to Russell Microcap Value Index	06-30	CI
Leap Therapeutics, Inc.(NasdaqCM:LPTX) added to Russell 3000E Value Index	06-30	CI
HC Wainwright Adjusts Price Target on Leap Therapeutics to $5.50 From $7, Maintains Buy Rating	05-14	MT
Leap Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Leap Therapeutics, Inc. announced that it has received $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP	04-14	CI
Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP	04-09	CI
Baird Adjusts Price Target on Leap Therapeutics to $9 From $11, Maintains Outperform Rating	03-19	MT
Leap Therapeutics Files $200 Million Mixed-Securities Shelf Registration	03-18	MT
Leap Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-18	CI
Leap Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-18	CI
Transcript : Leap Therapeutics, Inc. - Special Call	01-23
Leap Therapeutics, Inc. to Present New Clinical Data from Part A of Defiance Study At the 2024 Asco Gastrointestinal Cancers Symposium	01-16	CI
Transcript : Leap Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 01:30 PM	01-10
Leap Therapeutics, Inc. Announces Completion of Enrollment in Randomized Controlled Part C of the Distinguish Study of DKN-01 for the Treatment of Gastric Cancer Patients	01-02	CI
Mizuho Securities Adjusts Price Target on Leap Therapeutics to $12 From $20, Maintains Buy Rating	11-20	MT
Leap Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Top Premarket Decliners	23-10-16	MT
Top Premarket Decliners	23-10-09	MT
Baird Lowers Price Target on Leap Therapeutics to $20 From $30, Maintains Outperform Rating	23-08-15	MT
Leap Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Raymond James Adjusts Price Target on Leap Therapeutics to $18.50 From $17, Maintains Outperform Rating	23-07-13	MT

Chart Leap Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Its second clinical-stage program is FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. It also has two preclinical antibody programs, FL-302 and FL-501. FL-302 is a Claudin18.2/CD137 (also known as 4-1BB) bispecific antibody that is in preclinical development. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.

Sector

Biotechnology & Medical Research

Calendar

2024-08-08 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.24 USD

Average target price

11.38 USD

Spread / Average Target

+407.81%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
LEAP THERAPEUTICS, INC.	-45.96%	83.42M
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	127B
REGENERON PHARMACEUTICALS, INC.	+24.67%	117B
ARGENX SE	+25.44%	27.67B
BIONTECH SE	-17.74%	20.33B
GENMAB A/S	-15.17%	16.79B
BEIGENE, LTD.	-15.21%	15.63B
NEUROCRINE BIOSCIENCES, INC.	+11.91%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.65B
SAREPTA THERAPEUTICS, INC.	+54.50%	14.43B

Bio Therapeutic Drugs